Evidence review

Pine Bark for Blood Pressure

Pinus pinaster

The short answer

Early or mixed evidence

Possibly a little, if at all, and the effect is small. One meta-analysis of seven double-blind trials found no blood-pressure change; a larger 2025 review found systolic and diastolic pressure about 2 to 3 mmHg lower, with high disagreement between studies and mixed pine bark products. Many positive trials were linked to the maker of Pycnogenol, and an independent Stanford trial of a different pine bark extract found no benefit. It is not a replacement for prescribed blood pressure treatment.

8 key studies reviewed

Updated November 16, 2026

Key points

  1. 01

    Effect sizes are small, if real

    A 2025 meta-analysis found systolic pressure about 2.3 mmHg and diastolic about 2.6 mmHg lower. An earlier review of seven double-blind Pycnogenol trials found no significant change.

  2. 02

    Maker funding is common

    Cochrane found the manufacturer funded 20 of 27 pine bark trials across conditions. Several blood-pressure studies list Horphag scientists as co-authors or grant funders.

  3. 03

    Product and species matter

    Most positive work used Pycnogenol from Pinus pinaster. An independent Stanford trial of Flavangenol, a different pine bark extract, found no blood-pressure benefit.

  4. 04

    Not a substitute for medicine

    NCCIH says no dietary supplement matches blood pressure drugs. Lifestyle change and prescribed medicines remain the proven way to cut heart attacks and strokes.

  5. 05

    Blood thinners need a check first

    Pycnogenol reduces platelet clumping in smokers about as well as a dose of aspirin, though it did not lengthen bleeding time. Ask before combining it with anticoagulants.

Pine bark extract might lower blood pressure a little, but the effect is small and the evidence conflicts. Pycnogenol, a standardized extract of French maritime pine bark (Pinus pinaster), is the product behind most of the trials. A 2020 meta-analysis of seven double-blind, placebo-controlled trials with 626 people found no significant change in systolic or diastolic pressure. A larger 2025 review of pine bark extracts, pooling 20 blood-pressure trials, reported average falls of about 2 to 3 mmHg, with high disagreement between studies and a mix of branded extracts. Several of the better-known positive trials were co-authored or funded by people linked to Horphag Research, which makes Pycnogenol, and an independent Stanford trial of a different pine bark extract found no benefit. Nothing here is medical advice. High blood pressure needs a proper diagnosis and a treatment plan from a clinician; pine bark supplements do not replace prescribed blood pressure medicines.

High blood pressure (hypertension) affects almost half of US adults, according to the US National Center for Complementary and Integrative Health (NCCIH), and over time it can damage the heart, blood vessels, and kidneys, leading to heart attacks, heart failure, stroke, and chronic kidney disease. It is managed with lifestyle changes and, when those are not enough, with medicines that have been shown to reduce those complications. Pine bark extract is sold as capsules or tablets of standardized dry extract. Pycnogenol is a registered trademark of Horphag Research and is standardized to about 65–75% procyanidins (also called oligomeric proanthocyanidins, or OPCs). Labels that simply say “pine bark extract” may mean other pines, including radiata pine from New Zealand or Masson pine from China, or a generic product whose OPC percentage says nothing about the species. Results from one extract should not be assumed for another.

This page focuses on blood pressure evidence for Pycnogenol and related pine bark extracts: what the meta-analyses and key trials found, who paid for them, how large any effect appears to be next to lifestyle change and medicines, and who should be careful, especially people on blood thinners. It does not cover every use of pine bark. For the wider picture of heart-related herbs, see our heart guide; for another plant with more blood-pressure trials, see hibiscus.

02 The trials

Key studies

The trials and reviews that carry the most weight for this question, with the product and dose each one tested. Results apply to the preparation studied.

  1. Fogacci et al., 2020

    Systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials

    Who
    7 trials, 626 participants
    What and how much
    Pycnogenol (Pinus pinaster bark extract)
    How long
    Literature searched to 10 January 2019

    No significant effect on systolic pressure (WMD −0.028 mmHg; 95% CI −0.182 to 0.127), diastolic (−0.144 mmHg; −0.299 to 0.010), mean arterial, or pulse pressure. Results held in leave-one-out sensitivity analysis.

  2. Mohammadi et al., 2025

    Systematic review and meta-analysis of randomized controlled trials

    Who
    27 RCTs, 1,685 participants; blood pressure pooled from 20 trials
    What and how much
    Pine bark extracts including Pycnogenol, Oligopin, Flavangenol, Enzogenol, and others
    How long
    Literature searched to September 2024

    Systolic pressure 2.26 mmHg lower (95% CI −3.73 to −0.79) and diastolic 2.62 mmHg lower (−3.71 to −1.53), with high heterogeneity (I² about 81–82%). Authors declared no competing interests.

  3. Zhang et al., 2018

    Systematic review and meta-analysis

    Who
    9 trials, 549 participants
    What and how much
    Pycnogenol, 150–200 mg a day
    How long
    Literature searched to May 2016

    Systolic pressure 3.22 mmHg lower (95% CI −6.20 to −0.24) and diastolic 3.11 mmHg lower (−4.60 to −1.62). Larger effects in hypertensive participants or trials longer than 12 weeks, but not in the better-designed trials. Authors declared no conflict of interest.

  4. Drieling et al., 2010

    Randomized, double-blind, placebo-controlled; Stanford Prevention Research Center

    Who
    130 adults with raised cardiovascular risk, not on blood pressure drugs
    What and how much
    Flavangenol (Toyo-FVG), 200 mg a day; not Pycnogenol
    How long
    12 weeks

    Sum of systolic and diastolic pressure fell 1.0 mmHg on extract versus 1.9 mmHg on placebo (P = .87). No differences in lipids, glucose, insulin, or C-reactive protein. Safe but no cardiovascular benefit.

  5. Liu et al., 2004

    Randomized, double-blind, placebo-controlled, parallel-group

    Who
    58 adults with hypertension (mean age 57)
    What and how much
    Pycnogenol 100 mg a day plus nifedipine dose adjustment
    How long
    12 weeks

    Blood pressure control needed a lower mean nifedipine dose with Pycnogenol (15 mg) than with placebo (21.5 mg). Endothelin-1 fell and a prostacyclin marker rose versus placebo. Rohdewald, a long-time Pycnogenol researcher, was a co-author. Side effects were mild and similar between groups.

  6. Hosseini et al., 2001

    Randomized, double-blind, placebo-controlled crossover

    Who
    11 non-smoking adults with mild hypertension (SBP 140–159 and/or DBP 90–99 mmHg)
    What and how much
    Pycnogenol 200 mg a day
    How long
    8 weeks per period (16 weeks total)

    Systolic pressure fell significantly on Pycnogenol (reported from about 140 to 133 mmHg in later summaries); the diastolic fall was not significant versus placebo. Serum thromboxane fell (p < 0.05). Peter Rohdewald was a co-author.

  7. Enseleit et al., 2012

    Randomized, double-blind, placebo-controlled crossover; Horphag-funded

    Who
    23 adults with stable coronary artery disease on standard therapy
    What and how much
    Pycnogenol 200 mg a day on top of usual cardiovascular medicines
    How long
    8 weeks each period, with a 2-week washout

    Flow-mediated dilation rose from 5.3% to 7.0% on Pycnogenol and did not improve on placebo. Ambulatory systolic and diastolic blood pressure did not change. Funded by an unrestricted grant from Horphag Research (UK).

  8. Zibadi et al., 2008

    Randomized, double-blind, placebo-controlled, parallel-group

    Who
    48 adults with type 2 diabetes and mild to moderate hypertension on ACE inhibitors
    What and how much
    Pycnogenol 125 mg a day
    How long
    12 weeks

    58.3% on Pycnogenol achieved blood pressure control with a 50% cut in their pretrial ACE-inhibitor dose (p < .05). Endothelin-1, fasting glucose, HbA1c, and LDL cholesterol also improved versus placebo. Rohdewald was a co-author.

03 Evidence

What the research shows

Early or mixed evidence

Our rating for Pine Bark for Blood Pressure, based on the studies below.

The strictest Pycnogenol-only pooled analysis is by Fogacci and colleagues (Angiology 2020). They limited themselves to randomized, double-blind, placebo-controlled trials and found seven studies with 626 participants. The pooled change in systolic pressure was essentially zero (−0.028 mmHg; 95% confidence interval −0.182 to 0.127), and diastolic pressure was not clearly lower either (−0.144 mmHg; −0.299 to 0.010). Mean arterial and pulse pressure likewise did not change, and leaving out any single trial did not alter the result. Memorial Sloan Kettering Cancer Center (MSKCC) cites this review when it notes that a meta-analysis found no blood-pressure benefit with Pycnogenol. That null finding sits awkwardly beside earlier, broader reviews.

Zhang and colleagues (Iranian Journal of Public Health 2018), who declared no conflict of interest, pooled nine trials with 549 people taking 150–200 mg of Pycnogenol a day and reported systolic pressure 3.22 mmHg lower and diastolic 3.11 mmHg lower than control. The effect looked larger in people with hypertension and in trials lasting more than 12 weeks, but it disappeared when the analysis was limited to better-designed trials, and heterogeneity (how much results disagree) was extreme. Mohammadi and colleagues (BMC Complementary Medicine and Therapies 2025), whose authors also declared no competing interests, cast a wider net: 27 randomized trials of various pine bark extracts with 1,685 people, and blood pressure from 20 of them. Systolic pressure was 2.26 mmHg lower and diastolic 2.62 mmHg lower, again with I² around 81–82%. Their search included Pycnogenol, Oligopin, Flavangenol, Enzogenol (radiata pine), and other products, so the average is not a Pycnogenol-only estimate. Cochrane’s 2020 review of pine bark extracts for chronic disorders, by Robertson and colleagues, rated cardiovascular evidence very low certainty overall and noted that the manufacturer funded 20 of the 27 trials it included across all conditions.

Individual trials show why the averages disagree. Hosseini and colleagues (Nutrition Research 2001) gave 11 mildly hypertensive, non-smoking adults 200 mg of Pycnogenol or placebo in a crossover design for eight weeks each; systolic pressure fell significantly (later summaries report a drop from about 140 to 133 mmHg), diastolic pressure did not reach significance versus placebo, and serum thromboxane fell. The sample was tiny, and Peter Rohdewald, long associated with Pycnogenol research, was a co-author. Liu and colleagues (Life Sciences 2004) randomized 58 people with hypertension to 100 mg of Pycnogenol or placebo for 12 weeks while adjusting nifedipine; those on the extract needed a lower mean nifedipine dose (15 mg versus 21.5 mg) to keep pressure controlled, and endothelin-1 fell relative to placebo. Rohdewald was again a co-author. Zibadi and colleagues (Nutrition Research 2008), also with Rohdewald, enrolled 48 people with type 2 diabetes and hypertension on ACE inhibitors: after 12 weeks on 125 mg of Pycnogenol, 58.3% kept pressure controlled on half their previous ACE-inhibitor dose, and glucose, HbA1c, and LDL cholesterol improved. Drug-sparing designs like these do not prove that pine bark replaces modern treatment, and they were not independent of the product’s research network.

Independent and carefully instrumented trials look weaker on blood pressure itself. Drieling and colleagues at Stanford (Archives of Internal Medicine 2010) randomized 130 adults with raised heart risk, none on blood pressure medicine, to 200 mg a day of Flavangenol (Toyo-FVG), a Japanese water-based pine bark extract, or placebo for 12 weeks. The sum of systolic and diastolic pressure fell 1.0 mmHg on the extract and 1.9 mmHg on placebo (P = .87); lipids, glucose, insulin, and C-reactive protein did not differ. The product was not Pycnogenol, which limits how far the null result can be stretched, but it is the largest independent cardiovascular trial of a pine bark extract. Enseleit and colleagues (European Heart Journal 2012), in a University of Zurich crossover study of 23 people with stable coronary artery disease already on standard therapy, found that 200 mg of Pycnogenol a day for eight weeks improved brachial-artery flow-mediated dilation from 5.3% to 7.0%, while ambulatory blood pressure did not change. The trial was supported by an unrestricted grant from Horphag Research (UK). Better artery-wall function without a blood-pressure change is biologically interesting; it is not evidence that Pycnogenol treats hypertension.

Against that backdrop, NCCIH’s general advice on supplements for hypertension still applies: some products may have small effects, none has been shown to match prescription drugs, and people should not replace a prescribed plan with an unproven product. Lifestyle measures (healthy eating, activity, weight, limiting alcohol, and managing stress) and, when needed, antihypertensive medicines remain the interventions with hard outcome data on strokes and heart attacks. Open questions for pine bark include whether a large, independent, Pycnogenol-only trial in untreated hypertension would confirm even a 2–3 mmHg effect, how long any change lasts, and whether mixed-extract meta-analyses overstate a brand-specific signal.

04 In practice

How it was taken in studies

Blood-pressure trials of Pycnogenol mostly used 100–200 mg a day by mouth. Hosseini used 200 mg, Liu 100 mg, Zibadi 125 mg, and Enseleit 200 mg. LiverTox gives a typical Pycnogenol range of 100–200 mg a day. These figures describe a specific standardized extract and are not interchangeable with milligram amounts of other pine bark products or with raw bark teas. Capsules and tablets of dry extract were the trial forms; we found no controlled blood-pressure trial of homemade pine bark tea.

Trial durations were short. Blood pressure was judged at 8–12 weeks in the main hypertension studies, and Enseleit’s endothelial-function crossover used eight-week periods. No pine bark trial has shown that a few points off a clinic reading translate into fewer strokes or heart attacks. If a clinician agrees to a carefully labeled trial of a Pycnogenol product alongside lifestyle care, home readings before and after several weeks are the only practical way to notice either a small benefit or an excessive fall when medicines are also being taken.

Product identity matters more here than for many herbs. Choose a single-ingredient product that names Pinus pinaster (or French maritime pine), the bark extract, and preferably the brand actually studied, rather than a multi-herb “blood pressure” blend. Other pine bark extracts (Oligopin, Flavangenol, Enzogenol from Pinus radiata, Masson pine extracts) have different manufacturing histories; Mohammadi’s pooled average mixes several of them. Pine bark should sit, if at all, as a minor addition to the lifestyle changes NCCIH lists, never as a quiet swap for a prescribed medicine.

05 Caution

Before you try pine bark

At the doses used in trials, pine bark extract is usually well tolerated. LiverTox cites a review of 70 trials using 20–300 mg a day in which adverse events occurred in about 2.4% of participants, mainly stomach discomfort, dizziness, headache, and nausea, often at rates close to placebo. The Stanford trial reported similar adverse-event rates on extract and placebo. MSKCC also lists irritability and lower energy. LiverTox rates pine bark extract as unlikely to cause liver injury (likelihood score E). The blood-pressure trials themselves were small and short, so rare harms could have been missed.

Blood thinners are the main practical interaction. Pütter and colleagues (Thrombosis Research 1999) found that 100–125 mg of Pycnogenol prevented the rise in platelet aggregation caused by smoking about as well as 500 mg of aspirin, without lengthening bleeding time the way aspirin did. MSKCC therefore warns of increased bleeding risk with anticoagulants and antiplatelet drugs such as warfarin, aspirin, and clopidogrel. Enseleit’s coronary patients were already on aspirin and other heart drugs, and platelet adhesion did not change further in that small study, but that does not clear the combination for everyone. People with bleeding disorders, and anyone facing surgery, should check with their clinician; WebMD advises stopping pine bark at least two weeks before planned surgery. Meta-analyses also report small falls in fasting glucose and HbA1c, so people on diabetes medicines should watch for low blood sugar if they start or stop it, and Liu’s nifedipine-sparing trial plus Zibadi’s ACE-inhibitor results suggest it may add to blood pressure drugs.

Pregnancy and breastfeeding data are thin. WebMD rates maritime pine as possibly safe in later pregnancy based on limited study but advises caution, and recommends avoiding it while breastfeeding. Autoimmune disease is a theoretical caution because of laboratory immune-stimulating findings; WebMD advises people with multiple sclerosis, lupus, or rheumatoid arthritis to avoid it, though clinical harm has not been shown. Children should not be given pine bark for blood pressure; raised readings in a child need specialist assessment.

Pine bark is not for emergencies and not a substitute for treatment. The American Heart Association advises that if a reading is higher than 180/120 mmHg, you wait at least a minute and measure again; if it is still that high and you have chest pain, shortness of breath, back pain, numbness, weakness, a change in vision, or difficulty speaking, call 911 (or your local emergency number) rather than waiting to see whether it comes down. A reading that high without symptoms still needs prompt contact with a health care professional. See a doctor, too, if home readings stay raised, if you feel dizzy or faint after adding a supplement to blood pressure medicines, or if neurological symptoms appear. Never stop or reduce a prescribed blood pressure medicine because readings improve on pine bark: better numbers may simply mean the medicine is working, and NCCIH advises following the plan from your provider.

06 Questions

Frequently Asked Questions

Possibly a little, and only modestly if at all. A 2020 meta-analysis of seven double-blind pine bark (Pycnogenol) trials found no significant blood-pressure change. A 2025 review of mixed pine bark extracts reported average falls of about 2 to 3 mmHg, with high disagreement between studies. Many positive trials were linked to the maker, and no trial has shown fewer strokes or heart attacks. It does not replace prescribed treatment. Our heart guide puts this in context with other options.

No. Pycnogenol is Horphag Research’s trademarked extract of French maritime pine (Pinus pinaster) bark, standardized to about 65–75% procyanidins. Other supplements may use radiata pine, Masson pine, or unnamed “OPC” blends. An independent Stanford trial of Flavangenol, a different pine bark extract, found no blood-pressure benefit. Results for one product should not be assumed for another.

Hibiscus tea has more blood-pressure-focused trials and larger average systolic drops in some pooled analyses (around 7 mmHg), though Cochrane still judged that evidence insufficient. Pine bark’s pooled effects, when present, are smaller (about 2–3 mmHg) and more contested. See our hibiscus for blood pressure review for the tea and capsule evidence. Neither replaces blood pressure medicine.

Only with your prescriber’s knowledge. Trials by Liu and Zibadi suggested Pycnogenol may allow lower doses of nifedipine or ACE inhibitors while pressure stays controlled, which also means it could add to those drugs. Check home readings and report dizziness or fainting. Never stop or reduce a prescribed medicine on your own. Olive leaf and garlic raise similar add-on questions.

It may. Pycnogenol reduced smoking-induced platelet clumping about as well as 500 mg of aspirin in one study, though it did not lengthen bleeding time the way aspirin did. MSKCC warns of increased bleeding risk with anticoagulants and antiplatelet drugs. Tell your anticoagulation clinic or prescriber before starting or stopping regular pine bark extract.

Typical trial doses were 100–200 mg a day for 8–12 weeks (100 mg in Liu’s nifedipine study, 125 mg in Zibadi’s diabetes study, 200 mg in Hosseini and Enseleit). Those amounts refer to the branded extract, not to raw bark or other brands. Effects were measured after weeks, not after a single dose, and Enseleit found better artery dilation without a blood-pressure change.

Anyone with diagnosed hypertension should not rely on pine bark instead of medical care. Get urgent help for readings above 180/120 mmHg with chest pain, shortness of breath, or neurological symptoms. People on blood thinners, those with bleeding disorders, planned surgery, pregnancy or breastfeeding, or autoimmune disease should ask a clinician first. Lifestyle change and prescribed medicines remain first-line.

07 References

Sources

These references support the claims on this page. They are not an endorsement of any product. The pine bark monograph carries its own full source list.

  1. Effect of Pycnogenol on Blood Pressure: Findings From a PRISMA Compliant Systematic Review and Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled, Clinical Studies

    Angiology (PubMed 31763928), 2020

    Fogacci et al.: 7 RCTs, 626 participants; SBP WMD −0.028 mmHg (−0.182 to 0.127); DBP −0.144 (−0.299 to 0.010); no effect on mean arterial or pulse pressure.

  2. Does supplementation with pine bark extract improve cardiometabolic risk factors? A systematic review and meta-analysis

    BMC Complementary Medicine and Therapies (PubMed 39987124), 2025

    Mohammadi et al.: 27 RCTs, 1,685 people; SBP −2.26 and DBP −2.62 mmHg from 20 trials; I² ~81–82%; mixed extracts (Pycnogenol, Oligopin, Flavangenol, Enzogenol, others); no competing interests.

  3. Effect of Pycnogenol Supplementation on Blood Pressure: A Systematic Review and Meta-analysis

    Iranian Journal of Public Health (PubMed 30087862), 2018

    Zhang et al.: 9 trials, 549 participants, 150–200 mg/day; SBP −3.22 and DBP −3.11 mmHg; effect not seen in better-designed trials; no conflict of interest declared.

  4. No beneficial effects of pine bark extract on cardiovascular disease risk factors

    Archives of Internal Medicine (PubMed 20876405), 2010

    Drieling et al., Stanford: 130 adults; Flavangenol (Toyo-FVG) 200 mg/day for 12 weeks; SBP+DBP −1.0 vs −1.9 mmHg on placebo (P = .87); no lipid, glucose, or CRP benefit.

  5. Pycnogenol, French maritime pine bark extract, improves endothelial function of hypertensive patients

    Life Sciences (PubMed 14659974), 2004

    Liu et al.: 58 hypertensive patients; 100 mg Pycnogenol for 12 weeks; mean nifedipine dose 15 vs 21.5 mg; lower endothelin-1; Rohdewald co-author; mild GI, vertigo, headache, nausea.

  6. A randomized, double-blind, placebo-controlled, prospective, 16 week crossover study to determine the role of Pycnogenol in modifying blood pressure in mildly hypertensive patients

    Nutrition Research (DOI 10.1016/S0271-5317(01)00342-6), 2001

    Hosseini et al.: 11 mildly hypertensive adults; 200 mg/day for 8 weeks; significant systolic fall, non-significant diastolic vs placebo; thromboxane down; Rohdewald co-author.

  7. Effects of Pycnogenol on endothelial function in patients with stable coronary artery disease: a double-blind, randomized, placebo-controlled, cross-over study

    European Heart Journal (PubMed 22240497), 2012

    Enseleit et al.: 23 CAD patients; 200 mg/day for 8 weeks; FMD 5.3% to 7.0%; ambulatory BP unchanged; unrestricted grant from Horphag Research (UK).

  8. Reduction of cardiovascular risk factors in subjects with type 2 diabetes by Pycnogenol supplementation

    Nutrition Research (PubMed 19083426), 2008

    Zibadi et al.: 48 people with type 2 diabetes and hypertension on ACE inhibitors; 125 mg/day for 12 weeks; 58.3% controlled on 50% of prior ACE-inhibitor dose; Rohdewald co-author.

  9. Inhibition of smoking-induced platelet aggregation by aspirin and pycnogenol

    Thrombosis Research (PubMed 10498385), 1999

    Pütter et al.: 100–125 mg Pycnogenol prevented smoking-induced platelet aggregation similarly to 500 mg aspirin; aspirin raised bleeding time 167 to 236 seconds, Pycnogenol did not.

  10. Pine bark (Pinus spp.) extract for treating chronic disorders

    Cochrane Database of Systematic Reviews (PubMed 32990945), 2020

    Robertson et al.: 27 RCTs, 1,641 people, ten disorders; low or very low certainty throughout; manufacturer funded 20 of 27 trials; no definitive efficacy conclusions.

  11. Pine Bark Extract

    Memorial Sloan Kettering Cancer Center, About Herbs, 2025

    Cites Fogacci meta-analysis finding no BP benefit; anticoagulant/antiplatelet bleeding caution; irritability and lower energy; various pine species marketed.

  12. Hypertension (High Blood Pressure)

    National Center for Complementary and Integrative Health (NIH), 2018

    Almost half of US adults affected; lifestyle first; limited, small supplement effects; no supplement matches antihypertensive drugs; do not replace prescribed treatment.

  13. When To Call 911 About High Blood Pressure

    American Heart Association, 2025

    Readings higher than 180/120 mmHg: recheck after a minute; call 911 with chest pain, shortness of breath, back pain, numbness, weakness, vision change, or difficulty speaking.

  14. Maritime Pine: Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews

    WebMD, 2026

    Cautions for autoimmune disease, bleeding, surgery (stop 2 weeks prior), pregnancy, and breastfeeding; interactions with anticoagulants, diabetes drugs, and immunosuppressants.

Other herbs reviewed for heart & circulation

All evidence reviews →